Abiraterone-Associated Fulminant Liver Failure

Singh, Prabhsimranjot; Sinha, Ankur; Tamang, Tsering Gyalpo Lama; Chandra, Abhinav B.; Huang, Yiwu

doi:10.1097/mjt.0000000000000597

Cited by 6 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several cases of fatal fulminant hepatitis have been described after the drug was marketed. One case was published in the US in 2017 in a Chinese-American patient who developed fulminant hepatitis 8 weeks after the introduction of the drug, with death within 12 days of hospital admission ( 18 ). In Japan, seven cases were reported between 2014 and 2017, with three deaths, three remissions and no clear data on the outcome of the last case.…”

Section: Discussionmentioning

confidence: 99%

Fatal fulminant hepatitis in a patient taking abiraterone acetate: a case report

Akpokavie,

Gubert,

Abdelli

et al. 2023

Front. Med.

View full text Add to dashboard Cite

Abiraterone acetate is a steroidal inhibitor of cytochrome P450 17A1 indicated in the treatment of metastatic prostate cancer. This report examines the case of a 66-year-old patient diagnosed with prostate adenocarcinoma that had metastasized to the bones and lymph nodes. Treatment with abiraterone acetate and corticosteroid co-administration as well as LH-RH analog hormone therapy was initiated. Four and a half months later, the patient consulted for deterioration of general condition. Biologically, he developed a fulminant hepatitis of which he eventually died. An infectious or metabolic origin was ruled out. Oncological cause by either disease progression or second neoplastic process was eliminated by means of imaging. Hepatic toxicity was imputed to the treatment with abiraterone acetate. This case suggests that fulminant hepatitis on abiraterone acetate may be underestimated, and underscores the importance of regular monitoring of liver tests on this therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Fatal fulminant hepatitis in a patient taking abiraterone acetate: a case report

Akpokavie,

Gubert,

Abdelli

et al. 2023

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Colomba et al (2020) reported an rare increase in liver enzymes during treatment with abiraterone acetate in their study population with metastatic prostate cancer. Singh et al (2018) also reported the development of abiraterone-associated fulminant liver failure in one patient. Pilon et al (2017) conducted a large observational study and found that, among patients with metastatic prostate cancer, abiraterone acetate, compared with enzalutamide or chemotherapy, was associated with a significantly lower likelihood of having a central nervous system event.…”

Section: Introductionmentioning

confidence: 87%

Section: Introductionmentioning

confidence: 87%

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide

et al. 2021

View full text Add to dashboard Cite

Secondary hormone therapy, abiraterone and enzalutamide, has improved outcomes for metastatic castration-resistant prostate cancer (mCRPC) and prolonged patients’ lives significantly. Various studies have compared the cancer-related outcomes, adverse effects, and drug-induced comorbidities in patients with mCRPC who are treated with abiraterone or enzalutamide. However, few studies have explored associations between survival and comorbidities or comprehensive analyzed newly developed comorbidities during and after secondary hormone therapy. We attempted to clarify whether the Charlson comorbidity index (CCI) overall or itemized is predictive for overall survival, and we compared newly developed comorbidities between abiraterone and enzalutamide groups. We extracted data about expenses and comorbidities for patients who have mCRPC, received abiraterone and enzalutamide and met pre-examination operation criteria between September 2016 and December 2017 from the Taiwan National Health Insurance database. A total of 1153 patients with mCRPC who received abiraterone (n = 782) or enzalutamide (n = 371) with or without previous chemotherapy were included. We used the propensity score to match confounding factors, including age, pre-existing comorbidities, and precipitating factors for comorbidity (e.g., hypertension, hyperlipidemia), to eliminate selection bias in the comparison of newly developed comorbidities. Cox regression analysis was used for overall survival. We found that enzalutamide is superior to abiraterone with regard to overall survival. Our study revealed that there is no statistically significant difference in development of new comorbidities between abiraterone and enzalutamide group. Moreover, the CCI score, rather than any single item of the CCI, was a statistically significant predictor for overall survival.

show abstract

“…[34,35] ; l'origine asiatique des patients serait un facteur de risque probable[36]. Les taux de notification d'hépatites fatales rapportées en 2012 et 2014 (premières années de commercialisation du médicament) sont cohérents avec la fréquence rare mentionnée dans le RCP de Zytiga ®[7].…”

unclassified

Profils d’effets indésirables sous abiratérone et enzalutamide : analyse descriptive des données de la base nationale de pharmacovigilance

et al. 2021

View full text Add to dashboard Cite

show abstract

Abiraterone-Associated Fulminant Liver Failure

Cited by 6 publications

References 5 publications

Fatal fulminant hepatitis in a patient taking abiraterone acetate: a case report

Fatal fulminant hepatitis in a patient taking abiraterone acetate: a case report

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide

Profils d’effets indésirables sous abiratérone et enzalutamide : analyse descriptive des données de la base nationale de pharmacovigilance

Contact Info

Product

Resources

About